Scaling Supergut from Target Shelves to Global Gut Health Dominance

Supergut, the trailblazing gut health and GLP-1 nutrition brand, has closed a significant minority growth investment led by Full Frame Growth Partners, signaling its ambition to dominate the $51.6B digestive wellness market. The funding round, which includes participation from The Production Board, Cultivian Sandbox, and other notable investors, coincides with the appointment of Tracey Warner Halama—former CEO of Vital Proteins—as Supergut’s new CEO. Founder Marc Washington will transition to Executive Chairman, focusing on innovation and strategic expansion.

Why Investors Are Betting Big on Supergut

• Explosive Growth: Supergut’s revenue surged 172% in 2024, fueled by its GLP-1 Booster—a patented prebiotic fiber blend—and expansion into 5,000+ retail doors, including Target, GNC, and Sprouts.

• Clinical Evaluation: The brand remains the only gut health company with a gold-standard, peer-reviewed study proving its products reduce cravings, improve blood sugar control, and support weight management.

• Megatrend Alignment: Gut health and GLP-1 nutrition are projected to grow at 8.3% CAGR, with Supergut uniquely positioned at their intersection.

Scaling A Mission Driven Brand

Halama, who scaled Vital Proteins from $0 to $100M+ before its Nestlé acquisition, brings operational rigor to Supergut’s next chapter:

“Supergut has all the makings of a legacy brand—science-backed products, national retail distribution, and a purpose-driven mission. With tailwinds in fiber and GLP-1, we’re poised to redefine digestive health.”

Washington, who founded Supergut in 2022 to honor his late sister’s struggle with chronic illness, emphasized:

““Supergut has always been about more than just products—I founded the company in my sister’s memory to empower people to take control of their health through the science of the gut microbiome. I’m excited to partner with Tracey in bringing her proven leadership and experience building iconic wellness brands to amplify our bold mission at Supergut. In addition, Bader has helped shepherd several successful consumer investments over the last decade and I’m thrilled to have him join as our lead investor in this round.”

Strategic Priorities

1. Retail Domination: Double its retail footprint to 12,000 doors, with a focus on Amazon and mass-market chains.

2. Product Innovation: Expand its line of prebiotic shakes, bars, and powders, leveraging Washington’s scientific expertise.

3. Supply Chain Fortification: Strengthen sourcing and logistics to meet surging demand.

Bader Alam of Full Frame Growth Partners highlighted Supergut’s accessibility:

“Their products fit seamlessly into daily routines—whether you’re on Ozempic or simply seeking better gut health.”

A $100M+ Opportunity

Supergut’s success ties directly to the GLP-1 drug boom (70M potential U.S. users by 2028). Its products serve three roles:

• Boosts GLP-1 hormone production without injections.

• Reduces side effects like nausea and constipation for 56% of users.

• Helps maintain weight loss post-medication, addressing a 50% discontinuation rate.

Looking Ahead

With Halama steering operations and Washington driving innovation, Supergut aims to cement itself as the go-to brand for gut health. As retail partnerships expand and consumer awareness grows, the company is on track to join the ranks of household wellness icons—proving that science and purpose can fuel meteoric growth.

For those eager to try Supergut, its products are available at Target, GNC, and Amazon.

Learn more about Supergut’s clinical study in Diabetes, Obesity and Metabolism and explore their mission at supergut.com.